 |
市場調查報告書
商品編碼
1738474
個人化醫療的CRISPR的未來The Future of CRISPR in Personalised Medicine |
||||||
本報告深入探討了 CRISPR 技術在個人化醫療領域的變革性角色。它深入分析了 CRISPR-Cas9 及相關基因編輯工具如何徹底改變鐮狀細胞疾病和β地中海貧血等遺傳疾病的治療發展。報告深入分析了 CRISPR 相較於其他基因編輯技術的優點和局限性，以及提高 CRISPR 療法臨床療效所需應對的挑戰。
本報告也探討了新型 Cas 蛋白、鹼基編輯和主要編輯技術以及非病毒遞送平台在拓展 CRISPR 治療潛力方面的影響。報告還強調了基於 CRISPR 的體內和體外療法在治療更廣泛疾病方面的未來潛力，為應對這一快速發展的領域的醫藥專業人士提供了寶貴的視角。
關鍵問題解答
- 1.CRISPR 如何影響個人化醫療的發展？
- 2.與其他基因編輯工具相比，CRISPR-Cas9 有哪些優缺點？
- 3.為了改善以 CRISPR 為基礎的療法的臨床應用，需要解決哪些挑戰和障礙？
- 4.新型 Cas 蛋白、鹼基編輯和 Prime 編輯技術將如何影響基於 CRISPR 的療法的個人化？
- 5.非病毒遞送平台將在基於 CRISPR 的療法的發展中發揮什麼作用？
- 6.基於 CRISPR 的體內和體外療法在針對更廣泛疾病方面有哪些未來潛力？
主要企業
|
|
參加專家清單(摘錄)
- Alia Therapeutics基因·工程師(義大利)
- Epicrispr Biotechnologies技術開發部門上級董事(美國)
- Arbor Biotechnologies最高醫學負責人(美國)
- SNIPR Biome一起同成立者兼CEO(丹麥)
- Acuitas Therapeutics最高科學負責人(加拿大)
- Arbor Biotechnologies公司最高醫學負責人(美國)
- Editas Medicine社長兼CEO(美國)
方法論：
本報告基於獨立而簡潔的分析，該分析源自於專有的產業研究以及對產業思想領袖的深入訪談。報告深入分析了製藥企業高管需要了解的關鍵發展和市場趨勢，以應對未來的機會和挑戰。每份報告的重點都基於對二手文獻的回顧和已發現的知識缺口。基於這些初步研究，我們制定了基於證據、專家指導的討論指南，以確保研究能夠解答最重要的問題。此外，我們制定了嚴格的篩選標準，以確保受訪者擁有足夠的經驗、知識和資格就該主題發表意見。
我們的報告有何獨特之處？
FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助您掌握新興趨勢，有效應對複雜挑戰。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家存取獨家訪談和數據，以及持續的市場監測，讓您全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域，匯集了包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入和其他領域問題的看法，使您能夠做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。
This comprehensive report delves into the transformative role of CRISPR technology in the field of personalised medicine. It provides an in-depth analysis of how CRISPR-Cas9 and associated gene-editing tools are revolutionising the development of therapies for genetic disorders, including sickle-cell disease and beta-thalassemia. Gain insights into the advantages and limitations of CRISPR compared to other gene-editing technologies, as well as the challenges that need to be addressed to enhance the clinical efficacy of CRISPR-based therapies.
The report also explores the impact of novel Cas proteins, base editing and prime editing technologies, alongside non-viral delivery platforms, in expanding the therapeutic potential of CRISPR. Additionally, it highlights future opportunities for in vivo and ex vivo CRISPR-based therapeutics to target a broader spectrum of diseases, offering valuable perspectives for pharmaceutical professionals navigating this rapidly evolving landscape.
Key Questions Answered:
- 1. How has CRISPR impacted the development of personalised medicines?
- 2. What are the advantages and disadvantages of CRISPR-Cas9 compared to other gene editing tools?
- 3. What challenges and obstacles need to be addressed to improve the clinical profile of CRISPR-based therapies?
- 4. How will novel Cas proteins, base editing and prime editing technologies impact the personalisation of CRISPR-based therapies?
- 5. What role do non-viral delivery platforms play in advancing CRISPR-based therapeutics?
- 6. What are the future opportunities for in vivo and ex vivo CRISPR-based therapeutics to target a broader array of diseases?
Key Companies:
|
|
Partial List of Participating Experts:
- Genome Engineer, Alia Therapeutics, Italy
- Senior Director, Head of Technology Development, Epicrispr Biotechnologies, US
- Chief Medical Officer, Arbor Biotechnologies, US
- Co-founder and CEO, SNIPR Biome, Denmark
- Chief Scientific Officer, Acuitas Therapeutics, Canada
- Chief Medical Officer, Arbor Biotechnologies, US
- President and CEO, Editas Medicine, US
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
全球個人化醫療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年全球女性健康治療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年
美國禮賓醫療市場：市場規模、佔有率、趨勢分析（按所有權和專業）、細分市場預測（2025-2030 年）
禮賓醫療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按應用程式、所有權、最終用戶、地區和競爭細分，2020-2030 年預測個人化醫療外包市場規模、佔有率、趨勢分析報告：按階段、最終用途、服務、類型、最終用途、地區、細分預測，2025-2030 年
個人化醫療市場：按產品、應用和最終用戶分類 - 全球預測 2025-2030
個人化醫療生物標記市場，規模，佔有率，趨勢，產業分析報告:各適應症，各用途，各地區 - 市場預測，2025年～2034年
禮賓醫療保健市場規模、佔有率、成長分析（按專業、按所有權、按地區）- 產業預測，2024-2031 年個人化醫療生物標記市場規模、佔有率、趨勢分析報告：按應用、適應症、地區、細分市場預測，2025-2030個人化醫療市場規模、佔有率、成長分析，按產品、按應用、按最終用戶、按地區 - 產業預測，2024-2031年